Issued: London, UK

For media and investors only

Statement: Zantac (ranitidine) litigation

GSK plc (LSE/NYSE: GSK) welcomes the decision of the British Columbia Supreme Court in Dussiaume v. Sandoz Canada Inc. 2023 BCSC 795, dismissing a proposed class action on behalf of a class of ranitidine users in Canada.

Since 2019 there have been 13 peer-reviewed epidemiological studies conducted looking at human data regarding the use of ranitidine. The decision recognises that after more than three years of extensive study, the scientific consensus is that there is no consistent or reliable evidence that ranitidine increases the risk for any type of cancer.

The Court stated: “Given the uncontroverted evidence that neither ranitidine nor NDMA are reliably associated with increased cancer risk, and the absence of evidence that ranitidine or NDMA cause cancer in humans, the plaintiff has failed to raise a bona fide triable issue regarding injury due to the ingestion and/or purchase of ranitidine.”

GSK will continue to vigorously defend proposed class actions by ranitidine users that have been filed in Ontario and Quebec as well as individual actions filed by ranitidine users in Canada.

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D "Risk factors” in the company's Annual Report on Form 20-F for 2022, and Q1 Results for 2023 and any impacts of the COVID-19 pandemic.